Effect of Calcium Channel Blockers versus Diuretics for Hypertension

Yi Chunxue1, Zhang Jianming1, Wang Jianbing1

  • 1Chongqing University, Three Gorges Hospital, Chongqing, China.

Insights

Calcium channel blockers (CCBs) and diuretics show no significant difference in mortality or major cardiovascular events for hypertension patients. Further large trials are needed to fully validate these findings for clinical guidance.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Calcium channel blockers (CCBs) are a first-line treatment for hypertension.
  • The combination of CCBs with diuretics for hypertensive cardiovascular disease is controversial.

Purpose of the Study:

  • To evaluate the efficacy of CCBs compared to diuretics in managing hypertension.
  • To assess the impact of CCBs versus diuretics on cardiovascular outcomes.

Main Methods:

  • A systematic search of Cochrane Library, EMBASE, and PubMed databases was conducted.
  • The search included randomized controlled trials and meta-analyses from January 1991 to October 2021.
  • Keywords included "calcium channel blockers," "diuretics," and "hypertension."

Main Results:

  • No statistically significant difference in all-cause mortality was found between CCBs and diuretics in 5 studies (35,057 patients).
  • Major cardiovascular events did not differ significantly between CCBs and diuretics in 4 studies (33,643 patients).
  • Statistical heterogeneity (I²=0) was minimal across the analyzed studies.

Conclusions:

  • CCBs and diuretics demonstrate comparable cardiovascular clinical prognoses in hypertensive patients.
  • The findings suggest potential clinical implications, warranting validation through new large-scale randomized controlled trials.
Abstract

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
696
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
849
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
828
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
965
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
647
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
717